European Patent Office

T 1503/21 (Combination Tablet/ASTRAZENECA) vom 29.02.2024

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2024:T150321.20240229
Datum der Entscheidung
29. Februar 2024
Aktenzeichen
T 1503/21
Antrag auf Überprüfung von
-
Anmeldenummer
10782116.7
Verfahrenssprache
Englisch
Verteilung
Nicht verteilt (D)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
IMMEDIATE RELEASE TABLET FORMULATIONS
Name des Antragstellers
AstraZeneca AB
AstraZeneca UK Limited
Name des Einsprechenden
Hoefer & Partner Patentanwälte mbB
STADA Arzneimittel AG
Generics (U.K.) Limited
Galenicum Health S.L.U.
Kammer
3.3.07
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 123(2)European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(6)Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Schlagwörter
Inventive step - main request, auxiliary requests 1c, 2-6, 11b, 11c, 12-16 (no)
Inventive step - auxiliary request 17 (yes)
Amendments - auxiliary requests 7-9
Amendments - allowable (no)
Amendments - auxiliary request 17
Amendments - allowable (yes)
Claims - clarity
Claims - auxiliary request 17 (yes)
Sufficiency of disclosure - auxiliary reqeust 17 (yes)
Amendment to case - exercise of discretion
Orientierungssatz
-
Zitierte Akten
T 1287/14
Zitierende Akten
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside

2. The case is remitted to the opposition division with the order to maintain the patent in amended form based on the claims of the auxiliary request 17 as filed with the reply of the appellants (patent proprietors) on March 2022 and a description to be adapted thereto.